Cytochrome P-450 CYP2C8

A liver microsomal cytochrome P450 hydroxylase that oxidizes a broad spectrum of substrates including STEROIDS, FATTY ACIDS, and XENOBIOTICS. Examples of pharmaceutical substrates for CYP2C8 include; PACLITAXOL; torsemide; and; AMODIAQUINE

Also Known As:

CYP2C8; CYPIIC8; Cytochrome P450 MP-20; Cytochrome P450, Family 2, Subfamily C, Polypeptide 8; S-Mephenytoin 4-Hydroxylase; 4-Hydroxylase, S-Mephenytoin; CYP2C8, Cytochrome P-450; Cytochrome P 450 CYP2C8; Cytochrome P450 MP 20; P-450 CYP2C8, Cytochrome; P450 MP-20, Cytochrome; S Mephenytoin 4 Hydroxylase

Networked: 197 relevant articles (6 outcomes, 34 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Zeldin, Darryl C: 8 articles (11/2016 - 01/2005)
2.	Edin, Matthew L: 6 articles (11/2016 - 10/2010)
3.	Agúndez, José A G: 5 articles (01/2021 - 01/2006)
4.	García-Martín, Elena: 5 articles (01/2021 - 01/2006)
5.	Martínez, Carmen: 5 articles (01/2012 - 01/2006)
6.	McLeod, Howard L: 4 articles (11/2017 - 10/2007)
7.	Yi, Xingyang: 4 articles (09/2017 - 01/2015)
8.	Lih, Fred B: 4 articles (11/2016 - 10/2010)
9.	Lee, Craig R: 4 articles (05/2016 - 05/2007)
10.	Totah, Rheem A: 4 articles (05/2011 - 06/2008)

Related Diseases

1.	Adenocarcinoma 08/29/2023 - "In treatment naïve adenocarcinoma samples, the copy number multiplication of paclitaxel-metabolizing CYP2C8 and/or CYP3A4 was more prevalent in non-responder patients with progressive disease/exit than in responders with complete remission. " 11/03/2023 - "Expression of CYP3A5 protein is a basal and acquired resistance mechanism of pancreatic ductal adenocarcinoma cells conferring protection against the CYP3A and CYP2C8 substrate paclitaxel through metabolic degradation. "
2.	Neoplasms (Cancer) 01/01/2018 - "Downregulation of CYP2A6 and CYP2C8 in tumor tissues links to poorer OS and RFS in HCC patients." 01/01/2018 - "In addition, HCC patients with lower CYP2A6 and CYP2C8 in tumors had worse recurrence-free survival (RFS) than those with higher CYP2A6 and CYP2C8 (log ranks P = 0.02 and P = 0.012, respectively). " 01/01/2018 - "HCC patients with CYP2A6 and CYP2C8 low levels in tumor tissues suffered from poorer overall survival (OS) compared to those with high CYP2A6 and CYP2C8 in GSE14520 profile (log ranks P = 0.01 and P = 0.006, respectively). " 10/04/2016 - "Some of them are cancer related, such as POU2F3, NKD1 and CYP2C8, while LINC00189, GCC2 and OR9Q1 genes are rarely reported in human diseases. " 01/01/2013 - "In the pooled analysis with multiple cancer types, patients carrying the CYP2C8 rs1934951 AA or AG genotype showed no significantly increased BONJ susceptibility compared with those carrying the wild GG genotype [dominant: odds ratio (OR) = 2.05, 95% confidence interval (CI) = 0.67-6.29, p = 0.209; recessive: OR = 1.88, 95% CI = 0.23-15.6, p = 0.560; AG vs. GG: OR = 2.07, 95% CI = 0.80-5.32, p = 0.133, and AA vs. GG: OR = 1.34, 95% CI = 0.48-3.74, p = 0.578]. "
3.	Postoperative Pain 05/01/2021 - "In another analysis, the poor metabolizers for CYP2C8 and C9 presented lower levels of postoperative pain after 8 h and used rescue medication earlier than normal metabolizers. " 06/17/2022 - "To evaluate the possible association of CYP2C8 gene polymorphisms with the clinical efficacy and safety of ketorolac in relation to postoperative pain. " 06/17/2022 - "[Evaluation of the association of polymorphisms of the CYP2C8 gene with the efficacy and safety of ketorolac in patients with postoperative pain syndrome]." 01/01/2017 - "Efficacy of piroxicam for postoperative pain after lower third molar surgery associated with CYP2C83 and CYP2C9." 01/01/2017 - "The aim of this study was to evaluate the possible association of polymorphisms in the CYP2C83 and CYP2C9 genes with the clinical efficacy of oral piroxicam (20 mg daily for 4 days) after lower third molar surgeries with regard to postoperative pain, swelling, trismus, adverse reactions, need for rescue medication and the volunteer's overall satisfaction. "
4.	Body Weight (Weight, Body) 12/01/2006 - "Besides CYP2C8 genotype, body weight was a significant covariate (P < .001, log-likelihood ratio test). " 12/01/2018 - "Multivariable analysis indicated that consideration of baseline weight, body mass index, and CYP2C8, CYP3A4, and P-gp abundance strongly predicts steady-state dabrafenib trough concentration above 48 ng/mL (ROC AUC = 0.94; accuracy = 86%). " 11/01/2017 - "In univariate analysis, higher activity of CYP2C8 (regression β=0.22, P=0.020) and CYP2C9 (β=0.20, P=0.04), lower body weight (β=-0.014, P<0.0001), and endoxifen measurement during winter (each β<-0.39, P=0.002) were associated with higher endoxifen concentrations. " 04/01/2015 - "One hundred fifty Caucasian Italian outpatients with data on steady-state plasma concentrations of S- and R-warfarin were genotyped for CYP2C19 (2, 3, 4, 17), CYP2C9 (2, 3), CYP2C83, and VKORC12. The statistical analysis was performed on the effect of genotypes/haplotypes, age, sex, and body weight on the clearance of warfarin enantiomers and dose-normalized INR. "
5.	Adenoma (Adenomas) 11/10/2005 - "However, in normal tissue of patients with adenomas, protein levels of CYP2C8, CYP3A4 and CYP3A5, but not that of CYP2E1, were significantly lower than in biopsies obtained from disease-free controls. "

Related Drugs and Biologics

1.	Cytochrome P-450 CYP3A
2.	Cytochrome P-450 CYP2C9
3.	Paclitaxel (Taxol)
4.	Proteins (Proteins, Gene)
5.	Cytochrome P-450 CYP2C19
6.	Cytochrome P-450 CYP2E1 (CYP2E1)
7.	Warfarin (Coumadin)
8.	Piroxicam (Feldene)
9.	Mifepristone (RU 486)
10.	Androgen Receptors (Androgen Receptor)

Related Therapies and Procedures

1.	Castration
2.	Cytoreduction Surgical Procedures
3.	Therapeutics
4.	Drug Therapy (Chemotherapy)
5.	Pain Management